BTG supports Covestus on Dentyl and UltraDex brands acquisition

BTG, the financial and real estate advisory group, has supported Covestus on the acquisition of the Dentyl and UltraDex brands from Venture Life Group. 

Covestus operates a buy-and-build strategy in the consumer healthcare space, focusing on brands with strong clinical credentials and clear opportunities to improve brand recognition, product distribution or to pursue new product development opportunities. Its existing portfolio includes Probio7, a leading gut health supplement brand, and Sweatguard, a clinically proven solution for hyperhidrosis. 

The acquisition of Dentyl and UltraDex brands form part of an ambitious consolidation strategy aimed at creating a scaled platform of specialist healthcare brands addressing chronic conditions and preventative health needs.

BTG was enlisted by Covestus to provide financial due diligence services along with a review of the combined group forecast and structuring advice. The team advising on the deal was led by Partner Robert Insall. 

Robert Insall, Partner at BTG, said:

“It was a pleasure to work with the Maven and Covestus team to help them complete another acquisition.  Dentyl and UltraDex are exciting brands to acquire for the Group and we wish them every success under new ownership and are sure they will help Covestus continue to grow.”

Jonathan Oliver, Investment Director at Maven, said: 

“We are excited to have completed this acquisition, and it was great working again with the BTG team. They worked hard to meet challenging timelines and produced excellent and commercial input which has added plenty of value during the process.”